Passage Bio IPO

Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).

Register for Details

For more details on financing and valuation for Passage Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Passage Bio's ticker symbol?


What is Passage Bio's stock price?

1.0157 as of 5/26/23

Learn more about Passage Bio

Forge green plus iconForge green minus icon

What is Passage Bio funding to date?

Passage Bio has raised $225.5MM.
Forge green plus iconForge green minus icon

When was Passage Bio founded?

Passage Bio was founded in 2018.